SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cantel Medical Corp – ‘8-K’ for 1/9/20

On:  Thursday, 1/9/20, at 10:49am ET   ·   For:  1/9/20   ·   Accession #:  19446-20-2   ·   File #:  1-31337

Previous ‘8-K’:  ‘8-K’ on 12/20/19 for 12/18/19   ·   Next:  ‘8-K’ on 2/14/20 for 2/12/20   ·   Latest:  ‘8-K’ on 6/8/21 for 6/2/21

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 1/09/20  Cantel Medical Corp               8-K:7,9     1/09/20   13:4.1M

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     43K 
12: R1          Cover Cover                                         HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     12K 
13: XML         XBRL Instance -- a8kinvestorpresentatio_htm          XML     15K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- cmd-20200109_cal                XML      7K 
 5: EX-101.DEF  XBRL Definitions -- cmd-20200109_def                 XML      9K 
 6: EX-101.LAB  XBRL Labels -- cmd-20200109_lab                      XML     66K 
 7: EX-101.PRE  XBRL Presentations -- cmd-20200109_pre               XML     36K 
 3: EX-101.SCH  XBRL Schema -- cmd-20200109                          XSD     16K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
 9: ZIP         XBRL Zipped Folder -- 0000019446-20-000002-xbrl      Zip     30K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C: 
  Document  
 i false i 0000019446 0000019446 2020-01-09 2020-01-09


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 _________________________________________________________
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported)  i January 9, 2020
 cantellogo10k.jpg
  i Cantel Medical Corp.
(Exact name of registrant as specified in its charter)
 i Delaware
 i 22-1760285
(State or other jurisdiction
(Commission
(IRS Identification
of incorporation)
File Number)
Number)
 i 150 Clove Road
 i Little Falls
 i New Jersey
 i 07424
 
 i (973)
 i 890-7220
(Address of principal executive offices)
(Zip code)
 
(Registrant’s telephone number, including area code)

 (Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 i                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 i                                     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 i                                     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 i                                     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 i Common Stock
 i CMD
 i New York Stock Exchange
(Title of each class)
(Trading Symbol)
(Name of each exchange on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company  i 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 





Item 7.01              Regulation FD Disclosure

On January 9, 2020, representatives of the Company began making presentations to investors using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Investor Presentation”) and incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ending July 31, 2020.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements, Pro-Forma Financial Information and Exhibits

(d) Exhibits

Exhibit 99.1Investor Presentation in use beginning January 9, 2020 (furnished only).






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
CANTEL MEDICAL CORP.
 
 
 
 
 
By:
 
 
 
 
President and Chief Executive Officer
 
 
 




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
7/31/204
Filed on / For Period end:1/9/20
 List all Filings 
Top
Filing Submission 0000019446-20-000002   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:19:11.2am ET